OCGN logo

OCGN Ocugen, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.73
-0.01 (-0.95%)

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spe…

Market Cap: $248.44Mwww.ocugen.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
55
4 mentions
—
60d
51
10 mentions
—
90d
51
15 mentions
—
news: 15

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 1Sell 0Strong Sell 0
Avg price target$5+582.9%
Low $3.5Median $5High $6
Current Consensus

Revenue

$1.95M
$-193.0K$1.88M$3.96M$6.04M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.23
$-0.43–$-0.06
3 analysts
FY2026
$-0.20
$-0.23–$-0.17
5 analysts
FY2027
$-0.26
$-0.34–$-0.19
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Shankar Musunuri
Sector
Healthcare
Industry
Biotechnology
Employees
116
Beta
2.04
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-7.16
www.ocugen.com